Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Peter Charlish
Medtronic's outcomes-based insulin pump supply deal with Aetna is the latest example of the medtech industry's shift toward value-based care.
Liquid biopsies look set to revolutionize the management of cancer patients. A significant application could come in immuno-oncology, given the rapid uptake of IO drugs and the need to monitor changes in a patient’s immune profile over time to guide therapy selection.
The January deal with Singulex is just the latest in a long string of Qiagen's tie-ups with pharma and diagnostics partners. Herein, a five-year review of Qiagen's collaborations.
Singulex and Qiagen have entered a strategic alliance whereby Qiagen will be able to offer its clients companion diagnostic development services based on Singulex’s Single Molecule Counting technology.
Flatiron Health was formed to exploit a previously untapped source of real-world data on the treatment and clinical outcomes of cancer patients. The company is now working with most of the major players in the oncology sector as well as with the FDA to maximize the benefits of such data analytics.
The CTG Catapult aims to capture the commercial potential of the UK's cell and gene therapy research. To that end, it has constructed a GMP-compliant manufacturing facility in Stevenage.